F2G at IDWeek 2026
Oct 21–24, 2026 Washington, DC ~12k attendees Website
F2G brings 2 presentations to IDWeek 2026 in Washington, and exhibits at Booth 1340. Its program centres on olorofim for patients with invasive mould infections who have few treatment options. A late-stage randomized trial compares olorofim with AmBisome-based standard care for invasive aspergillosis when azole antifungals are unsuitable or have failed.
| Organization | IDWeek 2026 Attendance |
|---|---|
F2G Manchester, United Kingdom | |
Biotech developing olorofim, an oral antifungal from a new class, the orotomides, for invasive aspergillosis and other hard-to-treat mould infections. | Booth Exhibiting at Booth 1340 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Talk Thu Oct 22 10:42am–10:54am Olorofim versus AmBisome®-Based Standard of Care (SOC) for Treatment of Invasive Aspergillosis (IA) in Patients for Whom a Mold-Active Azole Antifungal (MAA) is Inappropriate or Ineffective (OASIS): A Phase 3, Randomized, Controlled, Adjudicator-Blinded Non-Inferiority (NI) Trial (NCT05101187) Antimicrobials, resistance and stewardship Poster Sat Oct 24 12:15pm–1:30pm Health-Related Quality of Life in Patients with Invasive Fungal Infections with Limited or No Treatment Options: An Analysis of the Phase 2b Olorofim Trial Data |
Instantly find 20 buyers from F2G
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by IDWeek, the Infectious Diseases Society of America (IDSA) or its partner societies (SHEA, HIVMA, PIDS and SIDP). Submit a correction